Geron Corporation (GERN) Q3 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

like to ask a question during this time, please press star 1 on your telephone keypad. I would now like to turn the call over to Dawn Scholdant, Senior Vice President, Investor Relations and Corporate Affairs. You may begin. Good morning, everyone. Welcome to the Geron Corporation third quarter 2025 earnings conference call. Before we begin, please note that during the course of this presentation and question and answer session, We will be making forward-looking statements regarding future events, performance, plans, expectations, and other projections, including those relating to the launch, commercial opportunity, and therapeutic potential of Ritello, anticipated clinical and commercial events, and related timelines. The sufficiency of general financial resources and other statements that are not historical facts. Actual events or results could differ materially. Therefore, I refer you to the discussion under the heading Risk Factors in Jaron's most recent periodic report filed with the SEC, which identifies important factors that could cause actual results to differ materially from those contained in the forward-looking statements and our future updates to those risk factors. Jaron undertakes no duty or obligation to update our forward-looking statements. Joining me on today's call are several members of Jaron's management team. Harut Samarjian, Chief Executive Officer, Michelle Robertson, Chief Financial Officer, and Dr. Joseph Ede, Executive Vice President of Research and Development and Chief Medical Officer. Ahmed El-Nawawi, our Chief Commercial Officer, will be introducing himself at the beginning of Q&A. Before handing the call over to Harut, I'd like to say I'm truly energized to join Geront. This is a company that can change the lives of patients with bloo...